Abstract
CC chemokine receptor 4 (CCR4) is generally recognized as a preferential marker for T helper 2 cells, and we have previously reported morpholine-derivative CCR4 antagonists, RS-1154 and RS-1269. Here, we investigate the pharmacological profiles of a novel pyrimidine-derivative CCR4 antagonist, 2-{4-[2-(diethylamino)ethoxy]phenyl}-N-(2,4-difluorobenzyl)-5-fluoropyrimidin-4-amine (RS-1748), which showed potency to inhibit the bindings of [(125)I]CCL17 and [(35)S]GTPgammaS to human CCR4-expressing Chinese hamster ovary (CHO) cells with IC(50) values of 59.9 nM and 18.4 nM, respectively. Furthermore, RS-1748 inhibited ovalbumin-induced airway inflammation in guinea pigs at a dose of 10 mg/kg. These results indicate that RS-1748 would be a promising lead compound for developing a therapeutic agent against asthma.
MeSH terms
-
Animals
-
Anti-Inflammatory Agents / pharmacology
-
Anti-Inflammatory Agents / therapeutic use*
-
Asthma / drug therapy
-
Bronchial Hyperreactivity / chemically induced
-
Bronchial Hyperreactivity / drug therapy*
-
Bronchial Hyperreactivity / metabolism
-
CHO Cells
-
Chemokine CCL17 / metabolism
-
Cricetinae
-
Cricetulus
-
Guanosine 5'-O-(3-Thiotriphosphate) / metabolism
-
Guinea Pigs
-
Humans
-
Inflammation / chemically induced
-
Inflammation / drug therapy*
-
Inflammation / metabolism
-
Inhibitory Concentration 50
-
Male
-
Ovalbumin
-
Pyrimidines / pharmacology
-
Pyrimidines / therapeutic use*
-
Receptors, CCR4 / antagonists & inhibitors*
Substances
-
2-(4-(2-(diethylamino)ethoxy)phenyl)-N-(2,4-difluorobenzyl)-5-fluoropyrimidin-4-amine
-
Anti-Inflammatory Agents
-
Chemokine CCL17
-
Pyrimidines
-
Receptors, CCR4
-
Guanosine 5'-O-(3-Thiotriphosphate)
-
Ovalbumin